uPAR-specific CAR T cells

N/A

Report date: 2023/05/19 18:05:26

Base Information

Drug NameuPAR-specific CAR T cells
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Urokinase plasminogen activator surface receptor
TargetsUrokinase plasminogen activator surface receptor
Therapy Area/IndicationsAging, Premature
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsAging, Premature
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A